TurnerTrends Stock Rating Report for ACOR
Data valid for week beginning July 14, 2008
|
ACOR [News]
|
Acorda Therapeutics Inc
|
Company Profile
"Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III development for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies- and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Thu, 17 Jul 2008 15:49:00 Etc/GMT | The Guru's Corner: Five biotech buys (at MarketWatch) | | Mon, 23 Jun 2008 20:08:27 Etc/GMT | Health Winners & Losers: Barrier Therapeutics (at TheStreet.com) | | Mon, 23 Jun 2008 15:05:24 Etc/GMT | Acorda Therapeutics falls following downgrade (AP) | | Mon, 23 Jun 2008 10:32:16 Etc/GMT | Acorda Therapeutics downgraded by Friedman Billings (Briefing.com) | | Fri, 20 Jun 2008 11:00:00 Etc/GMT | Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive Committee of Biotechnology Industry Organization (BIO) (Business Wire) | | Thu, 19 Jun 2008 20:27:40 Etc/GMT | 7 Stocks Defying the Doubters (at Motley Fool) | | Sat, 7 Jun 2008 10:43:00 Etc/GMT | [$$] Corning Keeps Charging Ahead (at Barron's Online) | | Wed, 4 Jun 2008 15:09:59 Etc/GMT | Acorda Therapeutics Now a Sell (Zacks.com) | | Tue, 3 Jun 2008 20:16:18 Etc/GMT | Royale Energy, HKN and Northern Oil and Gas among 52-week highs (SmallCapInvestor.com) | | Tue, 3 Jun 2008 18:17:32 Etc/GMT | Taking a Walk With a 10-Bagger (at Motley Fool) | | Tue, 3 Jun 2008 15:44:06 Etc/GMT | Surprising Low-Rated Stocks the Leaders Love (at Motley Fool) | | Tue, 3 Jun 2008 14:48:43 Etc/GMT | MS Drug Fampridine Sends Acorda Stock Way Up (at Seeking Alpha) | | Mon, 2 Jun 2008 20:55:03 Etc/GMT | Financial Woes Slam Stocks; GM Shines (at CNBC) | | Mon, 2 Jun 2008 20:53:00 Etc/GMT | TradingMarkets 7 Stocks You Need to Know for Tuesday (TradingMarkets.com) | | Mon, 2 Jun 2008 20:45:00 Etc/GMT | [$$] Stocks in the Spotlight Monday (at Barron's Online) | | Mon, 2 Jun 2008 20:24:46 Etc/GMT | Health Winners & Losers: ImClone (at TheStreet.com) | | Mon, 2 Jun 2008 19:12:00 Etc/GMT | Acorda Surges on Study Results for Multiple Sclerosis Drug (at The Wall Street Journal Online) | | Mon, 2 Jun 2008 17:50:12 Etc/GMT | Royale Energy, Acorda Therapeutics and Avant Immunotherapeutics lead small-cap percentage gainers (SmallCapInvestor.com) | | Mon, 2 Jun 2008 14:56:58 Etc/GMT | Acorda Drug Improves MS Walking Speeds (at TheStreet.com) | | Mon, 2 Jun 2008 14:38:29 Etc/GMT | ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online) | News provided by Yahoo! Finance |
|
